FrancophonIA/ELRC3.0 huggingface dataset:
English: This medicinal product is not intended for regular or continuous administration.
Maltese: Dan il-prodott mediċinali mhuwiex intiż għal għoti regolari jew kontinwu.
English: Fluciclovine (18F) is not indicated for use in women.
Maltese: Fluciclovine (18F) mhuwiex indikat għall-użu fin-nisa.
English: Urinary bladder wall Uterus
Maltese: Noduli limfatiċi pelviċi
English: Each mL of solution contains 1600 MBq fluciclovine (18F) at date and time of calibration (ToC).
Maltese: MBq ta' fluciclovine (18F) fid-data u l-ħin tal-kalibrazzjoni (ToC, time of calibration).
English: A CT scan should be obtained for attenuation correction and anatomic correlation.
Maltese: Għandu jinkiseb CT sken għall-korrezzjoni tal-attenwazzjoni u l-korrelazzjoni anatomika.
English: The full EPAR for Clopidogrel Krka can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Clopidogrel Krka is a ‘generic medicine'.
Maltese: Clopidogrel Krka huwa ‘mediċina ġenerika'.
English: Clopidogrel Krka clopidogrel
Maltese: Aktar tagħrif dwar Clopidogrel Krka
English: The active substance in Clopidogrel Krka, clopidogrel, is an inhibitor of platelet aggregation.
Maltese: Is-sustanza attiva ta' Clopidogrel Krka, il-klopidogrel, hija inibitur tal-aggregazzjoni tal-pjastrini.
English: This is a summary of the European public assessment report (EPAR) for Clopidogrel Krka.
Maltese: Dan id-dokument huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Clopidogrel Krka.
English: • atrial fibrillation (irregular rapid contractions of the upper chambers of the heart), when it should be given with aspirin.
Maltese: • ikollhom fibrillazzjoni atrijali (kontrazzjonijiet irregolari u mgħaġġla tal-kavitajiet ta' fuq tal-qalb), meta għandu jittieħed ma' aspirina.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Clopidogrel Krka on 23 September 2009.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq għal Clopidogrel Krka valida fl-Unjoni Ewropea kollha fit-23 ta' Settembru 2009.
English: Because Clopidogrel Krka is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Plavix.
Maltese: Peress li Clopidogrel Krka huwa mediċina ġenerika, l-istudji fuq in-nies ġew limitati għal testijiet biex jiddeterminaw il-bijoekwivalenza tiegħu mal-mediċina ta' referenza, Plavix.
English: This means that Clopidogrel Krka is similar to a ‘reference medicine' already authorised in the European Union (EU) called Plavix.
Maltese: Dan ifisser li Clopidogrel Krka huwa simili għall-‘mediċina ta' referenza' diġà awtorizzata fl-Unjoni Ewropea (UE) bl-isem ta' Plavix.
English: The standard dose is one 75-mg tablet once a day.
Maltese: Id-doża standard hija pillola ta' 75 mg waħda kuljum.
English: In acute coronary syndrome and atrial fibrillation, Clopidogrel Krka is used together with aspirin, the dose of which should not be higher than 100 mg.
Maltese: Fil-każi ta' sindromu koronarju akut u ta' fibrillazzjoni atrijali, Clopidogrel Krka jittieħed flimkien malaspirina u f'dan il-każ id-doża m'għandhiex taqbeż il-100 mg.
English: Clopidogrel Krka is available as tablets containing 75 mg clopidogrel.
Maltese: Clopidogrel Krka huwa disponibbli bħala pilloli li fihom 75 mg ta' klopidogrel.
English: This is then followed by the standard 75-mg dose once a day for at least four weeks (in ‘ST segment elevation' myocardial infarction) or for up to 12 months (in unstable angina or ‘non-Q-wave' myocardial infarction).
Maltese: Imbagħad il-kura titkompla b'doża standard ta' 75 mg darba kuljum tul tal-inqas erba' ġimgħat (fil-każi ta' infart mijokardijaku b'"elevazzjoni tas-segment ST") jew sa 12-il xahar (fil-każi ta' anġina instabbli jew infart mijokardijaku "mingħajr il-mewġa Q").
English: Clopidogrel Krka is used to prevent problems caused by blood clots in adults who have:
Maltese: Clopidogrel Krka jintuża biex jipprevjeni problemi kkawżati minn emboli tad-demm f'adulti li:
English: The Agency recommended that Clopidogrel Krka be approved for use in the EU.
Maltese: L-Aġenzija rrakkomandat li Clopidogrel Krka jkun approvat għall-użu fl-UE.
English: What are the benefits and risks of Clopidogrel Krka?
Maltese: X'inhuma l-benefiċċji u r-riskji ta' Clopidogrel Krka?
English: Why is Clopidogrel Krka approved?
Maltese: Għaliex ġie approvat Clopidogrel Krka?
English: Clopidogrel Krka contains the active substance clopidogrel.
Maltese: Clopidogrel Krka fih is-sustanza attiva klopidogrel.
English: Because Clopidogrel Krka is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Peress li Clopidogrel Krka huwa mediċina ġenerika u huwa bijoekwivalenti għall-mediċina ta' referenza, il-benefiċċji u r-riskji tiegħu jitqiesu l-istess bħal dawk tal-mediċina ta' referenza.
English: In acute coronary syndrome, treatment generally starts with a loading dose of four tablets.
Maltese: Fis-sindromu koronarju akut, ġeneralment il-kura tibda b'doża ta' inizjazzjoni ta' erba' pilloli.
English: Clopidogrel Krka can be started between a few days and 35 days after the attack;
Maltese: Clopidogrel Krka jista' jinbeda fl-ewwel ftit jiem wara l-attakk u sa 35 ġurnata wara;
English: Other information about Clopidogrel Krka
Maltese: Clopidogrel Krka jista
English: How is Clopidogrel Krka used?
Maltese: Kif jaħdem Clopidogrel Krka?
English: It is used in those patients who have at least one risk factor for vascular events such as a heart attack or stroke, cannot take vitamin K antagonists (other medicines that prevent blood clots) and are at low risk of bleeding.
Maltese: Jintuża f'dawk il-pazjenti li jkollhom tal-inqas fattur ta' riskju wieħed li jiżviluppawlhom problemi vaskulari bħal attakk tal-qalb jew puplesija, li ma jkunux jistgħu jieħdu antagonisti tal-vitamina K (mediċini oħra li jipprevjenu l-emboli tad-demm) u li jkunu f'riskju baxx li jkollhom fsada.
English: Further information on Renvela can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/renvela.
Maltese: Aktar informazzjoni dwar Renvela tinstab fis-sit elettroniku tal-Aġenzija: ema.europa.eu/medicines/human/EPAR/renvela.
English: Renvela (sevelamer carbonate)
Maltese: Renvela (karbonat ta' sevelamer)
English: Other information about Renvela
Maltese: Informazzjoni oħra dwar Renvela
English: Renvela is available as tablets (800 mg) and as powder (0.8 g, 1.6 g and 2.4 g) in a sachet to be taken 3 times a day with meals.
Maltese: Renvela jiġi bħala pilloli (800 mg) u bħala trab (0.8 g, 1.6 g u 2.4 g) f'qartas li għandhom jittieħdu tliet darbiet kuljum mal-ikliet.
English: Renvela received a marketing authorisation valid throughout the EU on 10 June 2009.
Maltese: Renvela ngħata awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha fl-10 ta' Ġunju 2009.
English: In a third main study in 49 adults who were not on dialysis, Renvela reduced phosphate levels from 2.0 mmol/l to 1.6 mmol/l.
Maltese: Fit-tielet studju ewlieni f'49 adult li ma kinux fuq id-dijaliżi, Renvela naqqas il-livelli ta' fosfat minn 2.0 mmol/l għal 1.6 mmol/l.
English: What are the risks associated with Renvela?
Maltese: X'inhuma r-riskji assoċjati ma' Renvela?
English: The active substance in Renvela, sevelamer carbonate, is a phosphate binder.
Maltese: Is-sustanza attiva f'Renagel, il-karbonat ta' sevelamer, hija legant tal-fosfat.
English: Renvela is a medicine used to control hyperphosphataemia (high blood phosphate levels) in:
Maltese: Renvela huwa mediċina użata biex tikkontrolla l-iperfosfatemija (livelli għoljin ta' fosfat fid-demm):
English: • adults and children from 6 years of age with chronic (long-term) kidney disease.
Maltese: • f'adulti u fi tfal minn 6 snin 'il fuq b'marda kronika (fit-tul) tal-kliewi.
English: Renvela (sevelamer carbonate) EMA/357790/2019
Maltese: EMA/357790/2019
English: In two main studies in 110 adults with kidney disease who were on dialysis, Renvela brought phosphate levels down to around 1.5-1.6 mmol/l (which is within or close to the normal range) and was as effective as another authorised medicine Renagel.
Maltese: F'żewġ studji ewlenin f'110 adulti b'mard tal-kliewi li kienu fuq id-dijaliżi, Renvela naqqas il-livelli ta' fosfat għal madwar 1.5-1.6 mmol/l (li huwa fil-firxa normali jew qribha) u kien effettiv daqs mediċina oħra approvata, Renagel.
English: As for all medicines, data on the use of Renvela are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Renvela hija ssorveljata kontinwament.
English: Finally, a main study also showed that Renvela was effective at lowering phosphate levels in 100 children: children who took Renvela had a greater reduction in phosphorous (0.87 mg/dl) than those taking placebo (a dummy treatment) who had a rise in phosphorous of 0.04 mg/dl.
Maltese: Fl-aħħar nett, studju ewlieni wera wkoll li Renvela kien effettiv biex inaqqas il-livelli ta' fosfat f'100 tifel u tifla: tfal li ħadu Renvela kellhom tnaqqis akbar fil-fosfru (0.87 mg/dl) minn dawk li kienu qed jieħdu plaċebo (kura finta) li kellhom żieda fil-fosfru ta' 0.04 mg/dl.
English: For the full list of side effects with Renvela, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji b'Renvela, ara l-fuljett ta' tagħrif.
English: The most common side effects with Renvela (which may affect more than 1 in 10 people) are nausea (feeling sick), vomiting, upper abdominal (belly) pain and constipation.
Maltese: L-effetti sekondarji l-aktar komuni b'Renvela (li jistgħu jaffettwaw aktar minn persuna 1 minn kull 10) huma nawżja (tħossok ma tiflaħx), remettar, uġigħ addominali fil-parti ta' fuq (fiż-żaqq) u stitikezza.
English: Studies show that Renvela is effective at reducing levels of blood phosphate in patients with hyperphosphataemia, and its side effects are considered manageable.
Maltese: Studji juru li Renvela huwa effettiv biex inaqqas il-livelli ta' fosfat fid-demm f'pazjenti b'iperfosfatemija, u l-effetti sekondarji tiegħu huma kkunsidrati ġestibbli.
English: What measures are being taken to ensure the safe and effective use of Renvela?
Maltese: X'miżuri qegħdin jittieħdu biex jiġi żgurat l-użu sigur u effettiv ta' Renvela?
English: Side effects reported with Renvela are carefully evaluated and any necessary action taken to protect patients.
Maltese: L-effetti sekondarji rrappurtati b'Renvela huma evalwati bir-reqqa u kull azzjoni meħtieġa hi meħuda biex tipproteġi lill-pazjenti.
English: Renvela has been shown in studies to be effective at lowering levels of blood phosphate in patients with hyperphosphataemia.
Maltese: Studji wrew li Renvela huwa effettiv biex jitbaxxew il-livelli ta' fosfat fid-demm f'pazjenti b'iperfosfatemija.
English: How does Renvela work?
Maltese: Kif jintuża Renvela?
English: Renvela should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease.
Maltese: Renvela għandu jintuża ma' kuri oħrajn bħal supplimenti tal-kalċju u l-vitamina D biex jipprevjeni liżvilupp ta' mard tal-għadam.
English: 100 units/ml
Maltese: 100 unità/ml
English: 6.1 List of excipients m-Cresol
Maltese: 6.1 Lista ta' eċċipjenti m-cresol
English: Date of first authorisation: 30th April 1996 Date of last renewal: 30th April 2006
Maltese: Data tal-ewwel awtorizzazzjoni: 30 ta' April 1996 Data tal-aħħar tiġdid: 30 ta' April 2006
English: Pack of 1, 2 and 5
Maltese: Pakkett ta' 1, 2 u 5
English: Dibasic sodium phosphate.7H2O
Maltese: Dibasic sodium phosphate.7H2O Zinc oxide
English: Fermentation
Maltese: Fertilità
English: 10 ml Vial: Pack of 1.
Maltese: Kunjett ta' 10 ml: Pakkett ta' 1.
English: Pack of 1
Maltese: Pakkett ta' 1
English: • fever, infection or emotional stress.
Maltese: • deni, infezzjoni jew stress emozzjonali.
English: Humalog 100 units/ml Junior KwikPen Lilly France S.A.S., Rue du Colonel Lilly, 67640 Fegersheim, France.
Maltese: Humalog 100 unità/ml Junior KwikPen Lilly France S.A.S., Rue du Colonel Lilly, 67640
English: Step 2: (For HUMALOG suspensions cloudy insulins only)
Maltese: Pass 2: (Għal suspensjonijiet ta' HUMALOG insulini mdardra biss)
English: Example: 10 ½ (10.5) units shown in the Dose Window
Maltese: ½ (10.5) unitajiet
English: Document Revision Date:
Maltese: Data ta' Reviżjoni tad-Dokument:
English: INFORMATION IN BRAILLE Humalog 100 units/ml Junior KwikPen
Maltese: INFORMAZZJONI BIL-BRAILLE Humalog 100 unità/ml Junior KwikPen
English: INFORMATION IN BRAILLE Humalog 200 units/ml
Maltese: INFORMAZZJONI BIL-BRAILLE Humalog 200 unità/ml
English: Dose Indicator
Maltese: Indikatur tad
English: • Additional risk minimisation measures (Humalog 200 units/ml)
Maltese: • Miżuri addizzjonali għall-minimizzazzjoni tar-riskji (Humalog 200 unità/ml)
English: Eli Lilly Ges.
Maltese: ELI LILLY
English: Local allergy is common (≥ 1/100 to <1/10).
Maltese: L-allerġija lokali hija komuni (≥ 1/100 to <1/10).
English: Each Humalog 200 units/ml KwikPen contains 600 units (3 millilitres).
Maltese: Kull Humalog 200 unità/ml KwikPen fiha 600 unità (3 millilitri).
English: 2 units.
Maltese: 4 unitajiet
English: • Humalog 200 units/ml KwikPen
Maltese: • Humalog 200 unità/ml KwikPen
English: Humalog KwikPen is available in two strengths, 100 units/ml and 200 units/ml.
Maltese: Humalog KwikPen issibu f'żewġ qawwijiet, 100 unità/ml u 200 unità/ml.
English: INFORMATION IN BRAILLE Humalog KwikPen
Maltese: INFORMAZZJONI BIL-BRAILLE Humalog KwikPen
English: • oral hypoglycaemics, (e.g. metformin, acarbose, sulphonylurea agents, pioglitazone,
Maltese: • mediċini ipogliċemiċi orali, (eż. metformin, acarbose, sustanzi sulphonylurea, pioglitazone, empagliflozin, impedituri ta' DPP-4 bħal sitagliptin jew saxagliptine),
English: Paediatric population Humalog can be used in adolescents and children (see section 5.1).
Maltese: Popolazzjoni pedjatrika Humalog jista' jintuża fl-adolexxenti u fit-tfal (ara sezzjoni 5.1).
English: It is not for use in 1.5 ml pens.
Maltese: M'għandux jiġi użat mal pinen ta' 1.5 ml.
English: The following related adverse reactions from clinical trials are listed below as MedDRA preferred term by system organ class and in order of decreasing incidence (very common: ≥1/10; common: ≥1/100 to <1/10; uncommon: ≥1/1,000 to <1/100; rare: ≥1/10,000 to <1/1,000; very rare: <1/10,000).
Maltese: MedDRA skont il-klassi tas-sistema u tal-organu u skont l-inċidenza tagħhom b'dawk li jseħħu l-aktar imniżżlin l-ewwel (komuni ħafna: ≥ 1/10; komuni: ≥ 1/100 sa < 1/10; mhux komuni: ≥ 1/1,000 sa < 1/100; rari: ≥ 1/10,000 sa < 1/1,000; rari ħafna: < 1/10,000).
English: Hypoglycemic Activity
Maltese: Attività Ipogliċemika
English: Pack of 1 and 5
Maltese: Pakkett ta' 1 u 5
English: Each KwikPen delivers 1-60 units in steps of 1 unit.
Maltese: Kull KwikPen tforni minn unità 1-60 unità f'żidiet ta' unità 1.
English: INFORMATION IN BRAILLE Humalog
Maltese: INFORMAZZJONI BIL-BRAILLE Humalog
English: The KwikPen dials half unit (0.5 unit) at a time.
Maltese: KwikPen iżżid nofs unità (0.5 unità) kull darba.
English: EU/1/96/007/002 EU/1/96/007/004 EU/1/96/007/020 EU/1/96/007/021 EU/1/96/007/023 EU/1/96/007/031 EU/1/96/007/032 EU/1/96/007/043 EU/1/96/007/044 EU/1/96/007/045
Maltese: EU/1/96/007/021 EU/1/96/007/023 EU/1/96/007/031 EU/1/96/007/032 EU/1/96/007/043 EU/1/96/007/044
English: Keep Throw Away
Maltese: Klipp tal
English: The pharmacokinetics of Humalog Mix25 are representative of the individual pharmacokinetic properties of the two components.
Maltese: Il-farmakokinetiċi ta' Humalog Mix25 jirreflettu l-propjetajiet farmakokinetiċi individwali taż-żewġ komponenti.
English: Preparing Humalog KwikPen
Maltese: Preparazzjoni ta' Humalog KwikPen
English: Humalog 100 units/ml KwikPen, Humalog Mix25 100 units/ml KwikPen, Humalog Mix50 100 units/ml KwikPen Humalog 200 units/ml KwikPen
Maltese: Humalog 100 unità/ml KwikPen, Humalog Mix25 100 unità/ml KwikPen, Humalog Mix50 100 unità/ml KwikPen Humalog 200 unità/ml KwikPen Lilly France S.A.S., Rue du Colonel Lilly, 67640
English: EU/1/96/007/044 5 pens
Maltese: EU/1/96/007/044 5 pinen
English: Preparing Humalog
Maltese: Preparazzjoni ta' Humalog
English: Insulin requirements may be increased by medicinal products with hyperglycaemic activity, such as oral contraceptives, corticosteroids, or thyroid replacement therapy, danazol, beta2 stimulants (such as ritodrine, salbutamol, terbutaline).
Maltese: Interazzjoni ma' prodotti mediċinali oħra u forom oħra ta' interazzjoni Il-ħtiġijiet ta' l-insulina jistgħu jiżdiedu bi prodotti mediċinali li għandhom attività ipergliċemika, bħal ma huma l-kontraċettivi orali, il-kortikosterojdi, jew terapija bl-ormoni tat-tirojde, danazol, stimulanti beta2 (bħal ma huma ritodrine, salbutamol, terbutaline).
English: 1 vial of 10 ml
Maltese: Kunjett 1 ta' 10 ml
English: Humalog with alcohol
Maltese: Humalog mal-alkoħol
English: • you take too much Humalog Mix25 or other insulin;
Maltese: • tieħu wisq Humalog mix25 jew insulina oħra;
English: Combination of Humalog with pioglitazone:
Maltese: It-teħid ta' Humalog flimkien ma' pioglitazone:
English: • nervousness or shakiness
Maltese: • nervożità jew rogħda
English: EU/1/96/007/041 5 pens
Maltese: EU/1/96/007/041 5 pinen
English: Humalog Mix50 consists of 50% insulin lispro solution and 50% insulin lispro protamine suspension.
Maltese: Humalog Mix50 tikkonsisti fi 50 % insulina lispro u 50 % suspensjoni ta' insulina lispro protamine.
English: The Humalog 100 units/ml KwikPen (and Humalog 200 units/ml KwikPen, see separate SmPC) delivers 1 - 60 units in steps of 1 unit in a single injection.
Maltese: Il-Humalog 100 unità/ml KwikPen (u l-Humalog 200 unità/ml KwikPen, ara l-SmPC separat) tagħti minn unità 1 - 60 unità f'żidiet ta' unità 1 f'injezzjoni waħda.
English: Preparing Humalog Mix25
Maltese: Preparazzjoni ta' Humalog Mix25
English: Each Humalog Junior KwikPen contains 300 units (3 millilitres).
Maltese: Kull Humalog Junior KwikPen fiha 300 unità (3 millilitri).
English: • If you do not see “0” in the Dose Window, do not redial.
Maltese: • Jekk ma tarax “0” fit-Tieqa tad-Doża,
English: Contains glycerol, zinc oxide, dibasic sodium phosphate7H20, metacresol and water for injections.
Maltese: Fih glycerol, zinc oxide, dibasic sodium phosphate7H20, metacresol u ilma għall-injezzjonijiet.
English: Preparing Humalog Mix50 KwikPen
Maltese: Preparazzjoni ta' Humalog Mix50 KwikPen
English: INFORMATION IN BRAILLE Humalog Mix50 KwikPen
Maltese: INFORMAZZJONI BIL-BRAILLE Humalog Mix50 KwikPen
English: INFORMATION IN BRAILLE Humalog Mix25 KwikPen
Maltese: INFORMAZZJONI BIL-BRAILLE Humalog Mix25 KwikPen
English: Preparing Humalog Mix25 KwikPen
Maltese: Preparazzjoni ta' Humalog Mix25 KwikPen
English: Dose Indicator Dose Knob
Maltese: Indikatur tad-Doża.
English: 5 pens of 3 mL.
Maltese: 5 pinen ta' 3 ml.
English: • not taking your Humalog or other insulin;
Maltese: • tieħu wisq Humalog jew insulina oħra;
English: INFORMATION IN BRAILLE Humalog Mix25
Maltese: INFORMAZZJONI BIL-BRAILLE Humalog Mix25
English: • You can give from half unit (0.5 unit) to 30 units in a single injection.
Maltese: • Tista' tagħti minn nofs unità (0.5 unitajiet) sa 30 unità f'injezzjoni waħda.
English: Humalog 200 units/ml KwikPen is used to treat diabetes.
Maltese: Humalog 200 unità/ml KwikPen huwa użat biex tiġi trattata d-dijabete.
English: Injecting Humalog
Maltese: Injetta Humalog
English: INFORMATION IN BRAILLE Humalog Mix50
Maltese: INFORMAZZJONI BIL-BRAILLE Humalog Mix50
English: Humalog works more quickly than normal human insulin because insulin lispro has been changed slightly in comparison to human insulin.
Maltese: Humalog jaħdem aktar malajr minn insulina umana normali għax l-insulina lispro ġiet mibdula ftit meta mqabbla mal-insulina umana.
English: Preparing Humalog Junior KwikPen
Maltese: Preparazzjoni ta' Humalog Junior KwikPen
English: You should normally use Humalog Mix25 within 15 minutes of a meal.
Maltese: Normalment għandek tuża Humalog Mix25 15-il minuta qabel ikla.
English: ELI LILLY ČR, s.r.o.
Maltese: Eli Lilly Slovakia, s.r.o.
English: Humalog KwikPen is available in two strengths.The Humalog 200 units/ml KwikPen (and Humalog 100 units/ml KwikPen, see separate SmPC) delivers 1 - 60 units in steps of 1 unit in a single injection.
Maltese: Il-Humalog 200 unità/ml KwikPen (u l-Humalog 100 unità/ml KwikPen, ara SmPC separat) tagħti minn unità 1 - 60 unità f'żidiet ta' unità 1 f'injezzjoni waħda.
English: Humalog Mix25 consists of 25% insulin lispro solution and 75% insulin lispro protamine suspension.
Maltese: Humalog Mix25 tikkonsisti fi 25 % soluzzjoni ta' insulina lispro u 75 % suspensjoni ta' insulina lispro protamine.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON (with blue box) multipack - Junior KwikPen
Maltese: KARTUNA INTERMEDJA (mingħajr il-kaxxa blu) parti minn pakkett multiplu - Junior KwikPen
English: QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 200 units insulin lispro*(equivalent to 6.9 mg).
Maltese: Kull ml fih 200 unità insulina lispro* (ekwivalenti għal 6.9 mg).
English: Pharmacotherapeutic group : Drugs used in diabetes, insulins and analogues for injection, fast-acting, ATC code: A10AB04
Maltese: Mediċini użati fid-dijabete, insulini u analogi għall-injezzjoni, jaħdmu malajr, Kodiċi ATC:
English: Preparing Humalog Mix50
Maltese: Preparazzjoni ta' Humalog Mix50
English: Dose Knob
Maltese: Buttun tad
English: The duration of action of the insulin lispro protamine suspension component of Humalog Mix25 is similar to that of a basal insulin (NPH).
Maltese: Mix25 huwa simili għall-insulina bażi (NPH).
English: Preparing Humalog 200 units/ml KwikPen
Maltese: Preparazzjoni ta' Humalog 200 unità/ml KwikPen
English: Clinical trials in patients with type 1 and type 2 diabetes have demonstrated reduced postprandial hyperglycaemia with Humalog Mix25 compared to human insulin mixture 30/70.
Maltese: Provi kliniċi f'pazjenti bid-dijabete tat-tip 1 u tat-tip 2 urew tnaqqis fl-ipergliċemija ta' wara l-ikel b'Humalog Mix25 mqabbla ma' taħlita 30/70 ta' insulina umana.
English: The symptoms include the following:
Maltese: Detentur tal-Awtorizzazzjoni għat-Tqegħid fis-Suq:
English: Each vial contains 1000 units of insulin lispro in 10 ml suspension.
Maltese: Kull kunjett fih 1000 unità ta' insulin lispro f'10 ml ta' suspensjoni.
English: Each vial contains 1000 units insulin lispro in 10 ml solution.
Maltese: Kull kunjett fih 1000 unità ta' insulina lispro f'10 ml ta' soluzzjoni.
English: Insulin lispro did not induce fertility impairment, embryotoxicity or teratogenicity in animal studies.
Maltese: L-insulina lispro ma kkaġunatx tnaqqis fil-fertilità, embrijutossiċità jew teratoġeniċità fi studji fuq l annimali.
English: The duration of action of the insulin lispro protamine suspension component of Humalog Mix50 is similar to that of a basal insulin (NPH).
Maltese: Mix50 huwa simili għall-insulina bażi (NPH).
English: Each Junior KwikPen delivers 0.5 - 30 units in steps of 0.5 units.
Maltese: Il-pinna tforni 0.5 - 30 unità f'żidiet ta' 0.5 unità.
English: Vial Store in a refrigerator (2°C - 8°C) or below 30°C.
Maltese: Aħżen fi friġġ (2°C - 8°C) jew taħt 30°C.
English: Use of Humalog in an insulin infusion pump
Maltese: Użu ta' Humalog ġo pompa tal-infużjoni tal-insulina
English: Injecting Humalog Mix25
Maltese: L-injezzjoni ta' Humalog Mix25
English: You should normally use Humalog Mix50 within 15 minutes of a meal.
Maltese: Normalment għandek tuża Humalog Mix50 15-il minuta qabel ikla.
English: MARKETING AUTHORISATION NUMBERS EU/1/96/007/043 1 pen
Maltese: NUMRU TAL-AWTORIZZAZZJONI GĦAT-TQEGĦID FIS-SUQ EU/1/96/007/043 pinna 1
English: - If you do not see insulin, repeat the priming steps, but not more than 4 times.
Maltese: - Jekk inti ma tarax insulina, irrepeti l passi tal-ikkargar iżda għal mhux aktar minn 4 darbiet.
English: Cap Clip Rubber Seal
Maltese: Klipp tal-Għatu
English: Injecting Humalog Mix50
Maltese: L-injezzjoni ta' Humalog Mix50